Inovio Biomedical to Present at International DNA Vaccine Conference |
 |
 |
| Monday, 06 July 2009 08:14 | ||||||||||||||||||||||||||||
|
Inovio scientists and associates will be making the following presentations:
About Inovio Biomedical Corporation Inovio Biomedical is engaged in the design, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The company’s SynCon™ technology enables the design of DNA-based vaccines capable of providing cross-protection against evolving, unmatched strains of pathogens such as influenza. Inovio’s proprietary electroporation-based DNA vaccine delivery technology has been shown by initial human data to safely and significantly increase gene expression and immune responses. Inovio’s clinical programs include HPV/cervical cancer (therapeutic) and HIV vaccines. An IND has been filed for an avian influenza vaccine. Partners and collaborators include Merck, Tripep, University of Southampton, University of Pennsylvania, and HIV Vaccines Trial Network. Inovio’s product candidates and technologies are protected by an extensive global intellectual property portfolio. More information is available at www.inovio.com. BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section Add this page to your favorite Social Bookmarking websites            |
SAN DIEGO--Inovio Biomedical Corporation (NYSE Amex:INO), a leader in DNA vaccine design, development and delivery, announced today that it will make multiple presentations at the Annual Conference of DNA Vaccines in Asia 2009 being hosted by the International Society of DNA Vaccines July 9 – 10 at the Beijing International Convention Center. The conference, with the theme, “Advancing DNA Vaccine Technology,” is co-chaired by David B. Weiner, Ph.D., professor of pathology, University of Pennsylvania School of Medicine, and chairman of Inovio’s scientific advisory board.
